ResMed revenue and financials

RMD · NYSE · USD

$220.69−0.97%−$2.17

Close · October 6, 2026

In the fiscal year ended June 2026, ResMed reported revenue of $5.65B (+9.85% year over year). Net income was $1.52B, a net margin of 26.9%.

Annual revenue · 2026: $5.65B
  1. $2.07B2017
  2. $2.34B2018
  3. $2.61B2019
  4. $2.96B2020
  5. $3.2B2021
  6. $3.58B2022
  7. $4.22B2023
  8. $4.69B2024
  9. $5.15B2025
  10. $5.65B2026

Fiscal year ending in June. Sources and method on the page Methodology and sources.

At a glance

Revenue growth
+9.85%
FY to Jun 2026 vs FY to Jun 2025
Net income growth
+8.75%
FY to Jun 2026 vs FY to Jun 2025
Net margin
26.9%
FY to Jun 2025: 27.2%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Total revenue1,4641,4311,4231,3361,3481,2921,2821,2251,2231,1971,1631,102
Cost of revenue594533536507519518523500500496508493
Gross profit870899887829829774759725724701655609
Selling, general and administrative293280276259265245242239242230222223
Research and development10694.391.087.386.483.981.479.580.977.173.975.7
Operating income452506500462457426417387381375339289
EBIT452506500462457426417387381375339289
EBITDA490558544504514464457426418411377327
Interest expense—————2.13.74.42.213.416.118.0
Pre-tax income474502496447458418418383358375259272
Income tax90.710410498.378.352.773.772.165.574.950.752.8
Net income383399393349380365345311292300209219
Net income to common shareholders383399393349380365345311292300209219
Basic EPS2.652.742.692.382.592.492.352.121.992.041.421.49
Diluted EPS2.642.742.682.372.582.482.342.111.982.041.421.49
Average shares (basic)145145146146146147147147147147147147
Average shares (diluted)145146146147147147147148148147148147
Dividend per share0.600.600.600.600.530.530.530.530.480.480.480.48